Excipients Formulation Development News Today

The facility features state-of-the-art labs, rapid prototyping capabilities, and ideation rooms.

Will serve as Telix’s primary manufacturing site for radioisotopes and commercial and clinical products.

To install an advanced mill for grinding finished APIs.

Will bolster manufacturing capacity and capabilities, adding approximately 40,000 sq.-ft. of combined assembly and warehousing space.

Adds an additional 12,000 square feet to Snapdragons API development and manufacturing facility.

Junshi Biosciences will grant a license to Dr. Reddy’s to develop and exclusively commercialize toripalimab in certain countries.

Transaction includes BPS manufacturing facilities and approximately 1,700 employees in Bloomington, IN and Halle, Germany.

Creates a total of 160,000 ft² of ambient cGMP biostorage capacity with 21,000 pallet locations.

The new space will increase laboratory space dedicated to analytical R&D activities for small molecules by more than 130%.

The two parties plan to collaborate to introduce more high-quality innovative drugs into Southeast Asian markets to achieve joint and long-term development.